Insmed Discontinues Brensocatib Development in Hidradenitis Suppurativa Following Phase 2b Failure

On April 7, 2026, Insmed Incorporated announced topline results from its Phase 2b CEDAR study evaluating brensocatib in 214 adult patients with moderate to severe hidradenitis suppurativa (HS). The study failed to meet its primary or secondary efficacy endpoints. Specifically, at Week 16, patients treated with brensocatib 10 mg and 40 mg showed a 45.5% and 40.3% reduction in total abscess and inflammatory nodule (AN) count, respectively, which was inferior to the 57.1% reduction observed in the placebo group. While brensocatib was well tolerated with no new safety signals identified—even at the highest 40 mg dose studied to date—the lack of efficacy has led Insmed to discontinue its development program for brensocatib in HS. The company intends to present the full data set at a future medical congress. Insmed will continue to focus on its other advanced programs in pulmonary and inflammatory conditions.